Prof Alison Birtle (Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK), Dr Ignacio Duran (Hospital Universitario Marqués de Valdecilla, Santander, Spain), Dr Laura Mertens (Netherlands Cancer Institute, Amsterdam, Netherlands), Prof Morgan Rouprêt (Pitié-Salpétrière Hospital, Paris, France) and Dr Patrizia Giannatempo (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) discuss bladder cancer updates from the first half of 2026.

The discussion covers current standards of care, including systemic therapies, bladder preservation approaches, and treatment strategies for both non-muscle invasive and advanced disease.

The panellists highlight how recent innovations, particularly in immunotherapy, targeted treatments, and novel combinations are reshaping the therapeutic landscape.

Key updates from major meetings, including ASCO 2026, ASCO GU 2026, and AUA 2026, are reviewed, with a focus on practice-changing data and emerging clinical evidence.

The panel also addresses how to effectively integrate new treatments into routine care, emphasising patient selection, sequencing strategies, and real-world considerations.

Overall, this conversation provides a comprehensive overview of where bladder cancer treatment stands today and where it is heading, offering practical insights for clinicians navigating a rapidly advancing field.